Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × TNBC × Clear all
NCT07491822 2026-03-24

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase NA Not yet recruiting
43 enrolled
Breast

TNBC

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

NCT05918133 2025-03-11

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Biotheus Inc.

Phase 1/2 Active not recruiting
42 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡